<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><description>肿瘤学临床研究及制药企业研发评述</description><managingEditor> (hellodword)</managingEditor><pubDate>Sat, 29 May 2021 23:28:08 +0800</pubDate><image><url>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</url><title>大叔快评 | wechat-feeds</title><link>http://MzA3NzY1MjAzNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>自发性细菌性腹膜炎！人血白蛋白请了解一下</title><link>https://mp.weixin.qq.com/s/MKfKhY7-if2ScYOSVYePvg</link><description></description><content:encoded><![CDATA[自发性细菌性腹膜炎！人血白蛋白请了解一下]]></content:encoded><pubDate>Sat, 29 May 2021 22:27:37 +0800</pubDate></item><item><title>【研究速递】水果和蔬菜的摄入与乳腺癌发病率：一项前瞻性研究的系统回顾和荟萃分析</title><link>https://mp.weixin.qq.com/s/GE08Exq9AwIPHpdm72QIKw</link><description></description><content:encoded><![CDATA[【研究速递】水果和蔬菜的摄入与乳腺癌发病率：一项前瞻性研究的系统回顾和荟萃分析]]></content:encoded><pubDate>Sat, 29 May 2021 22:27:37 +0800</pubDate></item><item><title>2021EHA大咖谈 | 胡凯教授：CAR-T治疗R/R DLBCL的分子遗传学背景及疗效</title><link>https://mp.weixin.qq.com/s/rrsO3kxXLhtGfK7axUWI2Q</link><description></description><content:encoded><![CDATA[2021EHA大咖谈 | 胡凯教授：CAR-T治疗R/R DLBCL的分子遗传学背景及疗效]]></content:encoded><pubDate>Sat, 29 May 2021 22:27:37 +0800</pubDate></item><item><title>武田制药发布2020财年全年财报：业绩保持稳健，利润率与现金流表现出色</title><link>https://mp.weixin.qq.com/s/jTYdvA4TbCphFUU4vwDGCA</link><description></description><content:encoded><![CDATA[武田制药发布2020财年全年财报：业绩保持稳健，利润率与现金流表现出色]]></content:encoded><pubDate>Fri, 28 May 2021 22:55:11 +0800</pubDate></item><item><title>【2021ASCO中国之声】剧透！梁爱斌教授解读2021ASCO两项中国CAR-T研究</title><link>https://mp.weixin.qq.com/s/AYk0kgFUazkO24njaNU-Ug</link><description></description><content:encoded><![CDATA[【2021ASCO中国之声】剧透！梁爱斌教授解读2021ASCO两项中国CAR-T研究]]></content:encoded><pubDate>Fri, 28 May 2021 22:55:11 +0800</pubDate></item><item><title>免疫单药或联合化疗治疗ROS1阳性NSCLC</title><link>https://mp.weixin.qq.com/s/gUpM0I97IZ-Wu1UYkgEFsA</link><description></description><content:encoded><![CDATA[免疫单药或联合化疗治疗ROS1阳性NSCLC]]></content:encoded><pubDate>Thu, 27 May 2021 21:40:38 +0800</pubDate></item><item><title>【2021ASCO】ZUMA-3研究的Ⅱ期结果：KTE-X19在R/R B-ALL成人患者显示出卓越的疗效</title><link>https://mp.weixin.qq.com/s/2mq5QJYPZ38OXDhdAlVv5A</link><description></description><content:encoded><![CDATA[【2021ASCO】ZUMA-3研究的Ⅱ期结果：KTE-X19在R/R B-ALL成人患者显示出卓越的疗效]]></content:encoded><pubDate>Thu, 27 May 2021 21:40:38 +0800</pubDate></item><item><title>武田中国创新挑战赛重磅启动，诚邀初创企业共赴数字医疗之途</title><link>https://mp.weixin.qq.com/s/oHbK0MzLX7W0JbQ4It3q7A</link><description></description><content:encoded><![CDATA[武田中国创新挑战赛重磅启动，诚邀初创企业共赴数字医疗之途]]></content:encoded><pubDate>Wed, 26 May 2021 22:53:13 +0800</pubDate></item><item><title>MM课堂 | 许贞书教授：蛋白酶体抑制剂的耐药机制研究</title><link>https://mp.weixin.qq.com/s/Z3WB4gNhnTb2mnPtKMWSwA</link><description></description><content:encoded><![CDATA[MM课堂 | 许贞书教授：蛋白酶体抑制剂的耐药机制研究]]></content:encoded><pubDate>Wed, 26 May 2021 22:53:13 +0800</pubDate></item><item><title>【EANO-ESMO临床实践指南】脑转移患者脑水肿和癫痫的诊断和治疗</title><link>https://mp.weixin.qq.com/s/9gIb2uLLhtww3D2WetMe_A</link><description></description><content:encoded><![CDATA[【EANO-ESMO临床实践指南】脑转移患者脑水肿和癫痫的诊断和治疗]]></content:encoded><pubDate>Wed, 26 May 2021 22:53:13 +0800</pubDate></item><item><title>ASCO I Keynote 811研究报告Her2阳性胃癌一线结果</title><link>https://mp.weixin.qq.com/s/Rmx-iWCbX-0sQxYbutznsA</link><description></description><content:encoded><![CDATA[ASCO I Keynote 811研究报告Her2阳性胃癌一线结果]]></content:encoded><pubDate>Tue, 25 May 2021 21:11:59 +0800</pubDate></item><item><title>MM课堂 | 安刚教授：MM免疫治疗进展ASH 2020</title><link>https://mp.weixin.qq.com/s/2WqdhdS_OwQ8lZ1WQ5co1Q</link><description></description><content:encoded><![CDATA[MM课堂 | 安刚教授：MM免疫治疗进展ASH 2020]]></content:encoded><pubDate>Tue, 25 May 2021 21:11:59 +0800</pubDate></item><item><title>蔡真教授：多发性骨髓瘤的治疗进展与挑战</title><link>https://mp.weixin.qq.com/s/AM00BSSmqZBRE0kIEcU51w</link><description></description><content:encoded><![CDATA[蔡真教授：多发性骨髓瘤的治疗进展与挑战]]></content:encoded><pubDate>Tue, 25 May 2021 21:11:59 +0800</pubDate></item><item><title>专访｜马军教授：维布妥昔单抗为淋巴瘤患者带来新选择，助力健康中国2030</title><link>https://mp.weixin.qq.com/s/7GOV14o2B-TPG8Ei03YX_w</link><description></description><content:encoded><![CDATA[专访｜马军教授：维布妥昔单抗为淋巴瘤患者带来新选择，助力健康中国2030]]></content:encoded><pubDate>Mon, 24 May 2021 23:09:24 +0800</pubDate></item><item><title>【2021 ICML】中国之声及维布妥昔单抗相关研究</title><link>https://mp.weixin.qq.com/s/DsTBGu9u0_7Lur7XpWxemA</link><description></description><content:encoded><![CDATA[【2021 ICML】中国之声及维布妥昔单抗相关研究]]></content:encoded><pubDate>Mon, 24 May 2021 23:09:24 +0800</pubDate></item><item><title>侯健教授：MM的新型靶向治疗</title><link>https://mp.weixin.qq.com/s/z8-5AVTmh8HlshgGKXwHtA</link><description></description><content:encoded><![CDATA[侯健教授：MM的新型靶向治疗]]></content:encoded><pubDate>Mon, 24 May 2021 23:09:24 +0800</pubDate></item><item><title>ASCO I J-ALEX研究五年随访，阿来替尼和克唑替尼的OS没有差别</title><link>https://mp.weixin.qq.com/s/7sLoljTigifr_xr-nJzPxw</link><description></description><content:encoded><![CDATA[ASCO I J-ALEX研究五年随访，阿来替尼和克唑替尼的OS没有差别]]></content:encoded><pubDate>Sun, 23 May 2021 17:48:36 +0800</pubDate></item><item><title>EGFR/ Met 双抗Amivantamab中文版说明书</title><link>https://mp.weixin.qq.com/s/R-Wmo2ty8KwbHKwqVC_jlQ</link><description></description><content:encoded><![CDATA[EGFR/ Met 双抗Amivantamab中文版说明书]]></content:encoded><pubDate>Sun, 23 May 2021 17:48:36 +0800</pubDate></item><item><title>【EHA2021】新型CD19/CD20 STAR-T细胞治疗R/R B-ALL</title><link>https://mp.weixin.qq.com/s/ZAmImdK7d-CV7GtGWTR4LQ</link><description></description><content:encoded><![CDATA[【EHA2021】新型CD19/CD20 STAR-T细胞治疗R/R B-ALL]]></content:encoded><pubDate>Sun, 23 May 2021 17:48:36 +0800</pubDate></item><item><title>看新闻 涨知识 I FDA授予武田抗巨细胞病毒药物（maribavir）优先审评资格</title><link>https://mp.weixin.qq.com/s/pyEe8uW_oo9fSi5sHtIG0Q</link><description></description><content:encoded><![CDATA[看新闻 涨知识 I FDA授予武田抗巨细胞病毒药物（maribavir）优先审评资格]]></content:encoded><pubDate>Sat, 22 May 2021 11:27:09 +0800</pubDate></item></channel></rss>